Podcasts about Refractory

Refractory epilepsy in veterinary medicine refers to a condition in which an animal with epilepsy fails to attain satisfactory seizure control or suffers intolerable side effects despite appropriate therapy with conventional anti-seizure drugs. Refractory epilepsy is an important problem in small animal practice as it occurs in approximately one-third of dogs with epilepsy. In this session, we discuss the reasons underlying this challenging situation in an individual patient and how this knowledge can help us develop improved therapeutic strategies.

Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  CE information and select publications here.

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos, Dr Hans Lee, and Dr Noopur Raje, moderated by Dr Joseph Mikhael, including the following topics:  Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Raje (3:17) Integrating Bispecific Antibodies into the Management of R/R MM — Dr Lee (20:38) Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators in Therapy for MM — Prof Dimopoulos (40:37) CE information and select publications

Severe refractory asthma, which affects approximately 1% to 5% of patients with asthma, is associated with increased morbidity and mortality. Author Juan Carlos Cardet, MD, MPH, of the University of South Florida joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the management of patients with severe refractory asthma, including first-line medications and biologics. Related Content: Management of Severe Refractory Asthma

In het zonnestelsel-in-wording HOPS-315 kunnen astronomen zien hoe ons eigen zonnestelsel er zo'n 4.6 miljard jaar geleden uit moet hebben gezien. En u hoort in deze aflevering hoe u een royale selectie van de muziek van deze podcast als album kunt kopen op Bandcamp.Witnessing a solar system's dawn, for the 1st time:https://earthsky.org/space/solar-systems-dawn-hops-315-silicon-monoxide/Refractory solid condensation detected in an embedded protoplanetary disk:https://www.eso.org/public/archives/releases/sciencepapers/eso2512/eso2512a.pdfHL Tauri (foto van protoplanetaire schijf):https://en.m.wikipedia.org/wiki/HL_TauriSteun de show en koop de muziek van deze podcast:https://henszimmermanaudio.bandcamp.com/album/really-slow-tapesDe Zimmerman en Space podcast is gelicenseerd onder een Creative Commons CC0 1.0 licentie.http://creativecommons.org/publicdomain/zero/1.0

Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children's Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children's Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents:- What are "CAR T" and "bispecific antibodies"?- What are the approved agents?- Selection of one therapy over another- Side effect profiles**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Send us a textSteve plays a bunch of BAD games and Trav...doesn't. Lots of good games coming out to look forward to. Kergon brings home the gold. Top 5 Death/Game Over Screens in Gaming (Potomax).Our next episode is Live on Twitch, September 27th at Noon Eastern. Games this episodeTrails in the Sky 1st Chapter (PlayStation 5, Switch, PC) – September 19Baby Steps (PlayStation 5, PC) – September 23Hades II (Switch 2, Switch, PC) – September 25Silent Hill f (PlayStation 5, Xbox Series X/S, PC) – September 25Sonic Racing: CrossWorlds (PlayStation 5, Xbox Series X/S, PlayStation 4, Xbox One, Switch, PC) – September 25Pac-Man World 2 Re-Pac (PlayStation 5, Xbox Series X/S, Switch 2, PlayStation 4, Xbox One, Switch, PC) – September 26Hotel Barcelona (PlayStation 5, Xbox Series X/S, PC) – September 26DE-EXIT: Eternal MattersHeartwormParanormal Activity: The Lost SoulThe King of Route 66 (PS2)Shinobi: Art of Vengeance (Switch)SilksongThe Midnight WalkSonic Adventure 2 (DreamCast)Find more shows at polymedianetwork.com, BlueSky: Trav, Steve, Polykill, Polymedia twitch.tv/blinkoom, Send us an email polykillpodcast@gmail.com, Check out our patreon at Patreon.com/polykill How to be a Polykiller: Beat a game, take a screenshot, post it on BlueSky or Polymedia Discord, use #justbeatit, write a review and be sure to include @Polykill. Beat the most, become Polykiller. Beat any, have your Skeet potentially read on the show! Check out the Bonus Beats episodes on Patreon for more beat-skeet coverage!

Adam's Paternity Leave is near its end, but while we still have a few weeks left of it, let's look at the first of a pair of episodes (we'll pick up the second installment next week) featuring a key Emmy presenter from last night. A few resourceful new Munchies have figured out a work-around where you can join as a free member and upgrade from there to a paid account which charges you for one month and unlocks the back catalog behind the respective tier of the paywall. After that first payment, you won't be charged again until we're dropping new content (which we'll warn everyone is coming), so if you want more of this it can be had, along with access to the fully uncut episodes from 100 to present and Movie Club episodes.Hot on the heels of an episode that nearly broke our rating scale, the Munchie Boys watched Part 1 of a two-parter featuring Ray Romano's kooky brother Robert from the hit turn-of-the-century sitcom for olds, Everybody Loves Raymond. Fans of that show will remember that the actor in question, Brad Garrett, is really, REALLY tall. This causes the kind of continuity problems that only SVU can create. We're obviously talking about complex genital geometry problems. We would, of course, be remiss if our discussion stayed on topic, so expect to hear about Chinese New Year, more car talk from Josh, Rikers Island, and Predator.Sources:A Look Inside Rikers - NY TimesMusic:Divorcio Suave - “Munchy Business”Thanks to our gracious Munchies on Patreon: Jeremy S, Jaclyn O, Amy Z, Diana R, Tony B, Barry W, Drew D, Nicky R, Stuart, Jacqi B, Natalie T, Robyn S, Amy A, Sean M, Jay S, Briley O, Asteria K, Suzanne B, Tim Y, John P, John W, Elia S, Rebecca B, Lily, Sarah L, Melsa A, Alyssa C, Johnathon M, Tiffany C, Brian B, Kate K, Whitney C, Alex, Jannicke HS, Roni C, Erin M, Florina C, Melissa H, and Olivia - y'all are the best!Be a Munchie, too! Support us on Patreon: patreon.com/munchmybensonBe sure to check out our other podcast diving into long unseen films of our guests' youth: Unkind Rewind at our website or on YouTube, Apple Podcasts, or wherever you listen to podcastsFollow us on: BlueSky, Facebook, Instagram, Threads, and Reddit (Adam's Twitter/BlueSky and Josh's BlueSky/Letterboxd/Substack)Join our Discord: Munch Casts ServerCheck out Munch Merch: Munch Merch at ZazzleCheck out our guest appearances:Both of us on: FMWL Pod (1st Time & 2nd Time), Storytellers from Ratchet Book Club, Chick-Lit at the Movies talking about The Thin Man, and last but not least on the seminal L&O podcast …These Are Their Stories (Adam and Josh).Josh discussing Jackie Brown with the fine folks at Movie Night Extravaganza, debating the Greatest Detectives in TV History on The Great Pop Culture Debate Podcast, and talking SVU/OC and Psych (five eps in all) on Jacked Up Review Show.Visit Our Website: Munch My BensonEmail the podcast: munchmybenson@gmail.comThe Next New Episode Once We're Back from Adam's Paternity Leave Will Be: Season 16, Episode 14 "Intimidation Game"Become a supporter of this podcast: https://www.spreaker.com/podcast/munch-my-benson-a-law-order-svu-podcast--5685940/support.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough can persist for years despite guideline-based therapy, significantly affecting patients' physical, social, and psychological wellbeing. Leading experts Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss explain how to distinguish RCC from other types of chronic cough, outline effective diagnostic strategies, and explore emerging treatment options. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and the Associate Chief of Clinical Research and Practice Innovation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough (RCC) is a debilitating condition that is often misunderstood and underdiagnosed, leaving patients with persistent symptoms despite standard treatment. Hear from Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss as they clarify the definition of RCC, outline essential diagnostic steps, and review current and emerging management strategies. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice and Operation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week's conversation!Episode contents:- What is the role of rituximab maintenance therapy? - What does surveillance after therapy look like? - What are options for treatment of patients who have relapsed follicular lymphoma? **** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode of The Poison Lab, host Ryan Feldman is joined by Dr. Joe Kennedy, medical toxicologist at the University of Vermont and consultant for the Northern New England Poison Center. Together they work through real poisoning cases to sharpen toxic differentials, sum up practical resuscitation priorities, and connect first-principles pharmacology to bedside decisions. They also answer listener questions on THAM vs bicarbonate, when to dialyze even with “normal” kidneys, and why rattlesnake antivenom costs so much—plus the real-world logistics of sourcing exotic antivenoms in the U.S.Dr. Kennedy and Ryan discuss the topics below. Looking for timestamps? Join the subscribed feed!Case set #1: Shock with hyperglycemia, big pupils, and probably NOT what you think it is. Case set #2: Massive bleeding after gas-station “herbal” productsCase set #3: Refractory wide-complex rhythms in a teen overdoseCase set #4: Sudden collapse at a hog farm- (SPOLIER) Recent outbreak of deaths as related to case 4Want the cases summarized and sent to you so you can come up with your differential before the show? SIGN UP FOR THE NEWS LETTER! Listener Q&ATHAM vs bicarbonate (closed vs open buffering; “breathe for bicarb, tinkle for THAM”)Why dialyze if the kidneys work? (EXTRIP-style thinking, gradients, and properties)Snake antivenom pricing & how zoos help hospitals obtain non-U.S. antivenomsCall outs from the showNACCT Abstracts!Clover coagulopathy!THAM VS BICARB ElectrolytesPotato quality video of dialysis from RyanArticle on snake antivenom costing >200,000 for one patientArticle on exotic antivenom procurementCase report Ryan published on treating blue Indonesian pit viperSupport the showReview the show where ever your listeningGet Messages from Toxo (Join the Newsletter!)Join as a supporting memberAd free episodesBonus content and early accessDiscounts and give aways on GOTA PICCEM Mushroom card gameThe GOTTA PICCEM Poisonous Mushroom Game! Tox trinkets (Rep the show at home!)Reach the showEmail: Toxtalk1@gmail.comMore Show ResourcesRyan's Medical Games and Resources

Send comments and feedbackIn a retrospective study of 31 patients with highly refractory epilepsy, 29% had more than a 50% reduction in seizures for at least 12 months after being treated with immunotherapy. Three of these patients became seizure free. Other than a trend toward a diagnosis of focal epilepsy, researchers did not identify any specific features predictive of treatment response. Sharp Waves spoke with the first author about the study and its implications.The study was published in Epilepsia in April 2025. Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.Let us know how we're doing: podcast@ilae.org.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Instagram, and LinkedIn.

In this podcast, expert faculty Atul Humar, MD, FRCP (C), and Camille Kotton, MD, FIDSA, FAST, take a deep dive into complex clinical scenarios and explore designing antiviral regimens for refractory CMV infections to minimize antiviral toxicities and maximize efficacy. Topics covered include:Management for suspected drug-resistant CMV infection Illustrative patient cases Gene mutations in CMV  Presenters:Atul Humar, MD, FRCPC, FASTProfessorDepartment of MedicineUniversity of TorontoEaton Family Chair in Transplant Infectious DiseasesAjmera Transplant CentreUniversity Health NetworkToronto, CanadaCamille Kotton, MD, FIDSA, FAST Clinical Director, Transplant and Immunocompromised Host Infectious DiseasesInfectious Diseases DivisionMass General Brigham Endowed Cancer Chair IVMassachusetts General HospitalAssociate Professor, Harvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/4lOa2kAGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications

Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.

Learn to appropriately modify antiviral therapy in solid organ transplant recipients with treatment-refractory cytomegalovirus (CMV) infections with expert faculty, Atul Humar, MD, FRCP (C). Topics covered include:Comparisons of available CMV antiviral therapies:Ganciclovir, valganciclovir, foscarnet, cidofovir, maribavirConsiderations for renal function monitoring with ganciclovir and valganciclovirA treatment algorithm for relapsed/refractory CMVThe latest clinical trial data and guideline recommendationsPresenter:Atul Humar, MD, FRCP (C) ProfessorDepartment of MedicineUniversity of TorontoEaton Family Chair in Transplant Infectious DiseasesAjmera Transplant CentreUniversity Health NetworkToronto, CanadaLink to full program:https://bit.ly/4lOa2kAGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify

Tune in to learn the fundamentals for timely identification of refractory cytomegalovirus (CMV) infections following solid organ transplantation from expert faculty, Camille Kotton, MD, FIDSA, FAST. Topics covered include:Direct and indirect effects of CMV infectionRisk factors for resistant/refractory CMVDefining resistant/refractory CMVPresenter:Camille Kotton, MD, FIDSA, FAST Clinical Director, Transplant and Immunocompromised Host Infectious DiseasesInfectious Diseases DivisionMass General Brigham Endowed Cancer Chair IVMassachusetts General HospitalAssociate Professor, Harvard Medical SchoolBoston, MassachusettsLink to full program:http://bit.ly/4lOa2kAGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In today's episode, we spoke with Nisha Joseph, MD, and Hans Lee, MD, about the FDA's accelerated approval of linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Joseph is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia. Lee is the director of Myeloma Research at the Sarah Cannon Research Institute in Nashville, Tennessee.  In our conversation, Drs Lee and Joseph discussed the significance of this approval, key data from the pivotal phase 1/2 LINKER-MM1 trial (NCT03761108), and where linvoseltamab fits into the relapsed/refractory myeloma treatment paradigm alongside other approved agents. 

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction: Multiple Myeloma — 2005 to 2025 (0:00) Questions from the Beginning (7:53) Choosing Options (13:54) Clinical Trials (18:03) Neuropathy (23:55) Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40) Bispecific Antibodies (35:18) Antibody-Drug Conjugates (43:08) Interacting with the Oncology Team (51:47) Other Questions (57:30) Educational and presenter information

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational and faculty information here.

Most men have no idea that they're stuck in a reflex loop that leads them straight to ejaculation. That's because your nervous system is wired for tension—and until you change that, you'll never access the full potential of your sexual energy.In this video, I break down:• Why the ejaculatory orgasm is a stress response• The nervous system pathway that leads to full-body, non-ejaculatory orgasm• How to start retraining your mind and body for deep, sustained pleasureThis isn't about tricks, edging, or squeezing your pelvic floor. It's about changing your entire relationship with pleasure. If you're serious about semen retention, multiple orgasms, and mastering your sexual energy—this video is your blueprint.Get my FREE Ebook - 3 Techniques for Legendary Ejaculation Control:

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still's disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.Featured ArticlesHeterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantabilityRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndromeMagrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML. Key topics included: •⁠  ⁠The importance of retesting for FLT3 mutations at the time of relapse •⁠  ⁠Treatment paradigms for fit vs. unfit patients •⁠  ⁠The role of Gilteritinib and combination therapies in relapsed settings •⁠  ⁠Management of side effects, including cytopenias and differentiation syndrome •⁠  ⁠Insights into the use of hypomethylating agents and the potential of oral therapies Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on the latest in oncology!

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases. In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab. Key topics covered included: • When to use bi-specific antibodies and how to manage side effects • The importance of MRD monitoring in treatment decisions • Insights on patient management in community oncology settings • The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. YouTube: https://youtu.be/05ieIyAIx_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

Dr. John Fleetham chats with Dr. Jaclyn Smith and Dr. Imran Satia about their articles, "Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)" and "Camlipixant: A New Hope for Refractory Chronic Cough?"

Drs Brian Lacy and Kyle Staller on Refractory Constipation by Gastroenterology Learning Network

Want to know how to recover from an ejaculation quickly and experience shorter refractory periods? The refractory period occurs after an ejaculatory orgasm, and is causes by hormonal and neurochemical changes in the body. With a bit of awareness around the factors that contribute to this, it's possible to lessen the intensity of the refractory period or avoid it entirely.In this video, I'm breaking down:• Why your refractory period gets worse as you age (and it's not what doctors tell you)• The truth about how porn is making 20-year-olds have the hormone profiles of 75-year-olds• Specific foods and supplements that can help get you back in action• The ancient sexual kung fu secrets that eliminate refractory periods entirelyGet my FREE Ebook - 3 Techniques for Legendary Ejaculation Control:

Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

In this episode of It Takes Balls, Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care explores everything from recurrence and refractory disease to the latest advancements in treatment and monitoring.Dr. Adra breaks down risk categories that guide treatment - good, intermediate, and poor - and explains how factors like tumor type and blood markers shape decisions about chemo, surgery, or surveillance. He also dives into the science behind relapse and platinum resistance.A major highlight of the episode is the discussion of innovative diagnostic tools like circulating tumor DNA (ctDNA) and microRNA-371. These biomarkers are making it possible to detect microscopic cancer earlier and more accurately, with the goal of reducing overtreatment and improving outcomes.Dr. Adra also shares insights on long-term monitoring, including the reality of late relapse, and emphasizes why annual checkups are crucial - even decades after treatment. For those with relapsed or refractory disease, he offers a hopeful look at cutting-edge therapies including targeted treatments, high-dose chemo, and upcoming CAR-T cell trials.Have a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgEmail Dr. Adra:nadra@iu.eduFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00) Bruton Tyrosine Kinase Inhibitors for FL (5:43) Anti-CD19 Antibodies for FL (9:40) Other Novel Agents Under Clinical Development for FL (18:50) Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06) Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07) Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

This week, Chad & Cy are once again joined by the most infamous guest in Middle Of Somewhere history... Mike Cronin (@BoneSnake3)! ⁠⁠Head on over to Chad's YouTube page to watch this episode!⁠⁠ This episode is brought to you by BetterHelp! Give online therapy a try at ⁠betterhelp.com/SOMEWHERE⁠ and get on your way to being your best self. --- Follow us on ⁠⁠Instagram⁠⁠! Chad Daniels (⁠⁠@ThatChadDaniels⁠⁠) is a Dad, Comedian, and pancake lover. With over 750 million streams of his 5 albums to date, his audio plays are in the 99th percentile in comedy and music on Pandora alone, averaging over 1MM per week. Chad's previous album, Footprints on the Moon was the most streamed comedy album of 2017, and he has 6 late-night appearances and a Comedy Central Half Hour under his belt. Cy Amundson (⁠⁠@CyAmundson⁠⁠) With appearances on Conan, Adam Devine's House Party, and Comedy Central's This is Not Happening, Cy Amundson is fast-proving himself in the world of standup comedy. After cutting his teeth at Acme Comedy Company in Minneapolis, has since appeared on Family Guy and American Dad and as a host on ESPN's SportsCenter on Snapchat. Learn more about your ad choices. Visit podcastchoices.com/adchoices

 As we celebrate yet another May the 4th (be with you), Mikey, d$ and #XlessDrEarl change up their Star Wars topics a bit - instead of fave scenes or ranking the movies, this time, its a look at all the movies that Star Wars inspired... some that turned out to be legendary... some that turned out to be legendarily bad... Can't Force alone, so the crew invites in Fan Fave and longtime friend of the show Hurricane Rhett Barnett, and he gives his own take on the 2024 comedy horror movie "Heretic" as well as a brief chat about the rerelease of "Revenge of the Sith", which has Mikey using the word "Refractory" and Rhett using the phrase "Marital Bed".   Then they play what turns about to be a disastrous version of "Everything Everywhere All At Once Upon a Time in Hollywood", which may end up being retired at some point because no one can play the stupid thing (note: d$'s opinion). Then, a top five of Star Wars Adjacent, with some classic Flash Gordon and a chat about Sam Jones and Jacko (OY!), plus star fighters and dark stars and stars with battles beyond them, plus a glave, a hole, Ridley Scott's inspiration, and even kitchen appliances in a classic short film.

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration of Bispecific Antibodies (15:21) The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34) Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34) Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24) Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14) Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Thanks to Dr. Abhinav Totapally who is a pediatric intensivist at Nicklaus Children's Hospital in Miami and Dr. Brian Bridges, the Division Chief of Pediatric Critical Care Medicine at the Medical University of South Carolina in Charleston for joining us for this series. Check out their paper published in PCCM in January 2025Learning Objectives:By the end of this podcast, listeners should be able to discuss:The rationale supporting and the limitations of using VA ECMO for children with refractory septic shock.Patient selection in the use of VA ECMO for children with refractory septic shock.The benefits and risks of common cannulation strategies for VA ECMO in children with refractory septic shock.An expert approach to supporting children with refractory septic shock on VA ECMO.Reference:Totapally A, Stark R, Danko M, Chen H, Altheimer A, Hardison D, Malone MP, Zivick E, Bridges B. Central or Peripheral Venoarterial Extracorporeal Membrane Oxygenation for Pediatric Sepsis: Outcomes Comparison in the Extracorporeal Life Support Organization Dataset, 2000-2021. Pediatr Crit Care Med. 2025 Jan 23.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Thanks to Dr. Abhinav Totapally who is a pediatric intensivist at Nicklaus Children's Hospital in Miami and Dr. Brian Bridges, the Division Chief of Pediatric Critical Care Medicine at the Medical University of South Carolina in Charleston for joining us for this series. Check out their paper published in PCCM in January 2025Learning Objectives:By the end of this podcast, listeners should be able to discuss:The rationale supporting and the limitations of using VA ECMO for children with refractory septic shock.Patient selection in the use of VA ECMO for children with refractory septic shock.The benefits and risks of common cannulation strategies for VA ECMO in children with refractory septic shock.An expert approach to supporting children with refractory septic shock on VA ECMO.Reference:Totapally A, Stark R, Danko M, Chen H, Altheimer A, Hardison D, Malone MP, Zivick E, Bridges B. Central or Peripheral Venoarterial Extracorporeal Membrane Oxygenation for Pediatric Sepsis: Outcomes Comparison in the Extracorporeal Life Support Organization Dataset, 2000-2021. Pediatr Crit Care Med. 2025 Jan 23.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

In this World Shared Practice Forum Podcast, Dr. Graeme MacLaren shares his expert insight on the outcomes of central versus peripheral cannulation techniques for Extracorporeal Membrane Oxygenation (ECMO) in pediatric patients with refractory septic shock as published in the February issue of Pediatric Critical Care Medicine. The discussion focuses on the implications of ECMO modality choices, the conditions affecting cannulation strategy, and how institutional resources can impact patient outcomes. LEARNING OBJECTIVES - Differentiate between central and peripheral venoarterial ECMO strategies in pediatric septic shock - Analyze key papers in the literature to provide context for decision-making around ECMO deployment in refractory septic shock - Identify factors influencing the success and outcome of ECMO in refractory pediatric septic shock cases - Apply considerations for patient selection and institutional resource availability in ECMO planning AUTHORS Graeme MacLaren, MBBS, MSc, FRACP, FCICM, FCCM, FELSO Director of Cardiothoracic Intensive Care, National University Hospital, Singapore Clinical Director of ECMO, National University Heart Centre, Singapore Adjunct Professor, Department of Surgery, National University of Singapore Past President, Extracorporeal Life Support Organization Jeffery Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: March 24, 2025. ARTICLES REFERENCED 1) MacLaren, Graeme MBBS, MSc, FELSO, FCCM. Cannulation Strategies for Extracorporeal Membrane Oxygenation in Children With Refractory Septic Shock. Pediatric Critical Care Medicine ():10.1097/PCC.0000000000003707, February 10, 2025. | DOI: 10.1097/PCC.0000000000003707 2) Totapally A, Stark R, Danko M, et al. Central or Peripheral Venoarterial Extracorporeal Membrane Oxygenation for Pediatric Sepsis: Outcomes Comparison in the Extracorporeal Life Support Organization Dataset, 2000-2021. Pediatr Crit Care Med. Published online January 23, 2025. doi:10.1097/PCC.0000000000003692 3) Schlapbach LJ, Chiletti R, Straney L, et al. Defining benefit threshold for extracorporeal membrane oxygenation in children with sepsis-a binational multicenter cohort study. Crit Care. 2019;23(1):429. Published 2019 Dec 30. doi:10.1186/s13054-019-2685-1 4) Bréchot N, Hajage D, Kimmoun A, et al. Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study. Lancet. 2020;396(10250):545-552. doi:10.1016/S0140-6736(20)30733-9 TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/84gbxthfmhvp7v9fsnjb87mh/0320425_WSP_MacLaren_Transcript.pdf Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. CITATION MacLaren G, Burns JP. Pediatric ECMO Cannulation Strategies in Refractory Septic Shock. 03/2025. OPENPediatrics. https://soundcloud.com/openpediatrics/pediatric-ecmo-cannulation-strategies-in-refractory-septic-shock-by-g-maclaren-openpediatrics.

Show notes at pharmacyjoe.com/episode1010. In this episode, I’ll discuss the use of dexmedetomidine to reduce vasopressor resistance in refractory septic shock. The post 1010: Does Dexmedetomidine Improve Vasopressor Sensitivity in Refractory Septic Shock? appeared first on Pharmacy Joe.

CardioNerds (Dr. Colin Blumenthal and Dr. Saahil Jumkhawala) join Dr. Rohan Ganti, Dr. Nikita Mishra, and Dr. Jorge Naranjo from the Rutgers – Robert Wood Johnson program for a college basketball game, as the buzz around campus is high. They discuss the following case involving a patient with ventricular tachycardia:  The case involves a 61-year-old man with a medical history of hypothyroidism, hypertension, hyperlipidemia, seizure disorder on anti-epileptic medications, and major depressive disorder, who presented to the ER following an out-of-hospital cardiac arrest. During hospitalization, he experienced refractory polymorphic ventricular tachycardia (VT), requiring 18 defibrillation shocks. Further evaluation revealed non-obstructive hypertrophic cardiomyopathy (HCM). We review the initial management of electrical storm, special ECG considerations, diagnostic approaches once ischemia has been excluded, medications implicated in polymorphic VT, the role of multi-modality imaging in diagnosing hypertrophic cardiomyopathy, and risk stratification for implantable cardioverter-defibrillator (ICD) placement in patients with HCM.  Expert commentary is provided by Dr. Sabahat Bokhari.   Episode audio was edited by CardioNerds Intern and student Dr. Pacey Wetstein.   US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - A Curious Case of Refractory Ventricular Tachycardia - Rutgers-Robert Wood Johnson Diagnostic Uncertainty in VT Storm: In VT storm, ischemia is a primary consideration; when coronary angiography excludes significant epicardial disease, alternative causes such as cardiomyopathies, channelopathies, myocarditis, electrolyte disturbances, or drug-induced arrhythmias must be explored.  ST elevations in ECG lead aVR:  ST elevations in lead aVR and diffuse ST depressions can sometimes represent post-arrest oxygen demand and myocardial mismatch rather than an acute coronary syndrome. This pattern may occur in the context of polymorphic VT (PMVT), where myocardial oxygen demands outstrip supply, especially after an arrest. While these ECG changes could suggest myocardial ischemia, caution is needed, as they might not always indicate coronary pathology. However, PMVT generally should raise suspicion for underlying coronary disease and may warrant a coronary angiogram for further evaluation.  Medication Implications in PMVT and HCM: Certain medications, including psychotropic drugs (e.g., antidepressants, antipsychotics) and anti-epileptic drugs, can prolong the QT interval or interact with other drugs, thereby increasing the risk of polymorphic VT in patients with underlying conditions like HCM. Careful management of these medications is critical to avoid arrhythmic events in predisposed individuals.  Multi-Modality Imaging in HCM: Cardiac MRI with late gadolinium enhancement (LGE) is invaluable in assessing myocardial fibrosis, a key predictor of arrhythmic risk, and can guide decisions regarding ICD implantation. Echocardiography and contrast-enhanced CT can provide additional insights into structural abnormalities and risk assessment.  Polymorphic VT in Nonobstructive HCM: Polymorphic ventricular tachycardia (PMVT) can occur in nonobstructive hypertrophic cardiomyopathy due to myocardial fibrosis and disarray, even in the absence of significant late gadolinium enhancement and left ventricular outflow tract obstruction.  ICD Risk Stratification in HCM: Risk stratification for ICD placement in HCM includes assessment of clinical features such as family history of sudden cardiac death, history of unexplained syncope, presence of nonsustained VT on ambulatory monitoring,

This week, we talk all about disseminated testicular cancer, highlighting our current treatment modalities and why we do what we do. We also cover refractory disease. This episode builds on our prior discussions in Parts 1 and 2, so be sure to check these out if you haven't already!Episode contents:- A history lesson about how we developed our current risk stratification model - Our current treatment paradigms and regimens for disseminated seminoma and non-seminoma - To resect or not to resect? - How we approach relapsed/refractory disease ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Show notes at pharmacyjoe.com/episode997. The post 997: The use of methylene blue for the treatment of refractory anaphylaxis without hypotension appeared first on Pharmacy Joe.